

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-70 (canceled).

Claim 71 (currently amended): A method for treating or inhibiting atherosclerosis by decreasing the formation or growth of plaque on arterial walls in a mammal comprising:

providing an agent for inhibiting an interaction between P-selectin and a ligand of P-selectin, said P-selectin being on an endothelial cell; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, said agent being administered repeatedly in sequential doses or by the controlled release to the mammal over a period of months or years,

wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1 which resemble PSGL-1 in shape and charge distribution, said agent being effective to inhibit the interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin.

Claims 72-80 (canceled).

Claim 81 (previously presented): The method of claim 71 wherein said P-selectin can bind to said PSGL-1 in the absence of said agent.

Claims 82 (canceled).

Claim 83 (canceled).

Claim 84 (canceled).

Claim 85 (previously presented): The method of claim 71 wherein said agent is administered in combination with other therapeutic agents.

Claim 86 (canceled).

Claim 87 (previously presented): The method of claim 71 wherein said mammal is human.

Claim 88 (previously presented): The method of claim 71 wherein said agent is administered in a dose of from about 0.01 mg/kg to about 200mg/kg of body weight.

Claim 89 (previously presented): The method of claim 71 wherein said agent is administered at a dose of about 100 mg/kg of body weight.

Claims 90-91 (canceled).

Claim 92 (currently amended): The method of claim 91 95, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

Claim 93 (canceled).

Claim 94 (currently amended): The method of claim 91 95, wherein said agent is administered in combination with other therapeutic agents.

Claim 95 (currently amended): A method for treating ~~restenosis~~ atherosclerosis in a mammal to which a vessel-corrective technique is administered comprising:

performing a vessel-corrective technique selected form the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery on a mammal; and

administering to said mammal, after said vessel-corrective technique, an effective amount of an agent selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1 which resemble PSGL-1 in shape and charge distribution, said agent being administered repeatedly in sequential doses or by the controlled release to the mammal over a period of months or years to decrease the formation or growth of plaque on the arterial walls of the mammal such that the restenosis occurring after said vessel corrective technique is thereby treated.

Claim 96 (new): The method of claim 71 wherein the agent is administered over a period of years.

Claim 97 (new): The method of claim 95 wherein the agent is administered over a period of years.